BiotechTube
Home/Viracta Therapeutics/Daniel R. Chevallard
DR

Daniel R. Chevallard

Former COO and CFO

Viracta Therapeutics

Therapeutic Areas

OncologyInfectious Disease (Virus-associated)

Viracta Therapeutics Pipeline

DrugIndicationPhase
Nanatinostat + Valganciclovir (Nana-val)Relapsed/Refractory EBV+ Lymphomas (PTCL, CTCL, DLBCL)Phase 2

Leadership Team at Viracta Therapeutics

DP
Darrel P. Cohen
Former Chief Medical Officer
IR
Ivor Royston
Former CEO, President, and Co-Founder
MR
Mark Rothera
Former President and CEO
JK
John K. H. North
Former Chairman of the Board
View full Viracta Therapeutics profile